Recommendations for observational studies of comorbidity in multiple sclerosis
dc.contributor.author | Marrie, Ruth Ann | |
dc.contributor.author | Miller, Aaron | |
dc.contributor.author | Sormani, Maria Pia | |
dc.contributor.author | Thompson, Alan | |
dc.contributor.author | Waubant, Emmanuelle | |
dc.contributor.author | Trojano, Maria | |
dc.contributor.author | O'Connor, Paul | |
dc.contributor.author | Fiest, Kirsten | |
dc.contributor.author | Reider, Nadia | |
dc.contributor.author | Reingold, Stephen | |
dc.contributor.author | Cohen, Jeffrey A. | |
dc.date.accessioned | 2019-01-24T21:11:55Z | |
dc.date.available | 2019-01-24T21:11:55Z | |
dc.date.issued | 2016 | |
dc.description.abstract | Objective:To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies.Methods:We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity.Results:We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed.Conclusion:Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS. | |
dc.description.grantingagency | National Multiple Sclerosis Society | |
dc.description.grantingagency | ECTRIMS | |
dc.description.grantingagency | Don Paty Career Development Award from the MS Society of Canada | |
dc.description.grantingagency | Manitoba Research Chair from Research Manitoba | |
dc.description.grantingagency | International Advisory Committee on Clinical Trials in Multiple Sclerosis | |
dc.description.grantingagency | European Committee for Treatment and Research in Multiple Sclerosis | |
dc.description.grantingagency | US National Multiple Sclerosis Society | |
dc.identifier.citation | Marrie, R. A., Miller, A., Sormani, M. P., Thompson, A., Waubant, E., … Trojano, M. (2016). Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 86(15), 1446–1453. https://doi.org/10.1212/wnl.0000000000002474 | |
dc.identifier.doi | 10.1212/WNL.0000000000002474 | |
dc.identifier.doi | http://dx.doi.org/10.11575/PRISM/35781 | |
dc.identifier.issn | 0028-3878 | |
dc.identifier.uri | http://hdl.handle.net/1880/109522 | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
dc.publisher.department | Critical Care Medicine | |
dc.publisher.faculty | Cumming School of Medicine | |
dc.publisher.hasversion | Published version | |
dc.publisher.policy | http://www.neurology.org/open-access/neuro | |
dc.rights | © 2016 American Academy of Neurology | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Epidemiology | |
dc.subject | Medical/Systematic disease | |
dc.subject | Multiple sclerosis | |
dc.title | Recommendations for observational studies of comorbidity in multiple sclerosis | |
dc.type | Review |
Files
Original bundle
1 - 5 of 8